News & Announcements

201231_Top_Holders_Report (91)

December 23, PharmAust Commences MPL Manufacture for Human Clinical Trials

News & Announcements 2020By Richard Mollard December 23, 2020

201223_PAA_Syngene_FightMND_Manufacture

December 22, PharmAust Set to Commence Phase IIb Anticancer Canine Trial

News & Announcements 2020By Richard Mollard December 22, 2020

201222_PhaseIIbcaninetrial

December 21, Epichem Awarded DNDi Extension

News & Announcements 2020By Richard Mollard December 21, 2020

201221_EpichemDNDi

December 4, Issued Capital

News & Announcements 2020By Richard Mollard December 4, 2020

201204_IssuedCapital

November 30, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard December 1, 2020

201130_Top_Holders_Report

November 5, AGM Results

News & Announcements 2020By Richard Mollard November 5, 2020

201105_AnnualGeneralMeeting

October 31, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard November 2, 2020

201031_Top_Holders_Report (87)

2020 Annual General Meeting Notice

News & Announcements 2020By Richard Mollard October 2, 2020

201002_2020_Annual General Meeting

September 30, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard October 1, 2020

Top_Holders_Report (84)

ONJCRI Monepantel Signalling Pathway Update

News & Announcements 2020By Richard Mollard September 29, 2020

200929_PAA_ONJCRI Update

LUMC COVID-19 Clarification Statement

News & Announcements 2020By Richard Mollard September 28, 2020

200928_Clarification Statement on LUMC and COVID-19 work

LUMC and PAA Agreement for COVID-19 Work

News & Announcements 2020By Richard Mollard September 24, 2020

200924_LUMC-PAA-Agreement

200921_PharmAust Awarded FightMND Grant for Phase I Trial

News & Announcements 2020By Richard Mollard September 21, 2020

200921_PAA_FightMND

14 September, Shareholder Update

News & Announcements 2020By Richard Mollard September 14, 2020

200914_Shareholder Update

Elanco not to Exercise Agreed Option

News & Announcements 2020By Richard Mollard September 9, 2020

200909_Elanco not to Exercise Agreed Option

Monepantel Anti-Covid-19 Activity Confirmed

News & Announcements 2020By Richard Mollard September 9, 2020

200909_Monepantel Anti-Covid-19 Activity Confirmed

August 31, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard September 1, 2020

200831_Top_20_Holders

Epichem waste-to-fuels technology partnership

News & Announcements 2020By Richard Mollard September 1, 2020

200901_Epichem waste to fuels technology partnership

Appendix 4E & Preliminary Final Report

News & Announcements 2020By Richard Mollard August 31, 2020

200831_Appendix 4E & Preliminary Final Report

Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells

News & Announcements 2020By Richard Mollard August 25, 2020

200825_Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells

July 31, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard August 1, 2020

200731_top20shareholders

28 July Appendix 4C and Quarterly Update

News & Announcements 2020By Richard Mollard July 28, 2020

200728_Appendix4CandQuarterlyUpdate

13 July, Final Report delivered under Option Agreement

News & Announcements 2020By Richard Mollard July 13, 2020

200713_Final Report Option Agreement

June 30, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard July 1, 2020

200701_topShareholders

JP Equity Partners – Broker Analyst Report – July 2020

News & Announcements 2020, Research Notes 2020By PharmAust June 30, 2020

PAA Research Report – June 2020

24 June, Shareholder Update

News & Announcements 2020By Richard Mollard June 24, 2020

200624_ShareholderUpdate

18 June, Confirmation of Covid-19 Monepantel Results

News & Announcements 2020By Richard Mollard June 18, 2020

18 June Confirmation of Covid-19 Monepantel Results

18 June, Reinstatement of Official Quotation

News & Announcements 2020By Richard Mollard June 18, 2020

18 June, Reinstatement of Official Quotation

15 June, Voluntary Suspension

News & Announcements 2020By Richard Mollard June 15, 2020

2200615_Voluntary Suspension

4 June, Preliminary Monepantel SARS-CoV-2 Data

News & Announcements 2020By Richard Mollard June 4, 2020

200604_Preliminary Monepantel SARS-CoV-2 Data

May 31, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard June 1, 2020

200602_Top_Holders_Report

12 May, Phase II Trial – Successful Anti-Cancer Outcome

News & Announcements 2020By Richard Mollard May 12, 2020

200512_Phase II Trial Update – Successful Outcome

April 30, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard April 30, 2020

200501_top20shareholders

30 April, Appendix 3G Notification of Issue, Conversion or Payment of Equity + Securities

Financial Reports 2020, News & Announcements 2020By Richard Mollard April 30, 2020

200430_Performance rights

20 April, Appendix 4C and Quarterly Update

Financial Reports 2020, News & Announcements 2020By Richard Mollard April 20, 2020

200420_Appendix 4C and Quarterly Update

17 April, PharmAust and WEHI evaluate monepantel for COVID-19 in vitro

News & Announcements 2020By Richard Mollard April 17, 2020

200417_Monepantel in SARS-CoV-2

31 March, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard March 31, 2020

200401_Top_Holders

31 March, Expiry of Options

Financial Reports 2020, News & Announcements 2020By Richard Mollard March 31, 2020

200313_Expiry of Options

31 March, Phase II Trial Update

News & Announcements 2020By Richard Mollard March 31, 2020

200313_Phase II Dog Trial Update

3 March, Brisbane Animal Referral Hospital Joins PharmAust Phase II Dog Cancer Trial

News & Announcements 2020By Richard Mollard March 3, 2020

200403_Expansion of Sites

29 February, Top 20 Shareholders

News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard February 29, 2020

200229_Top_Holders_Movements_Report

28 Feb, Appendix 4D & Half Year Report

Financial Reports 2020, News & Announcements 2020By Richard Mollard February 28, 2020

200228_Appendix 4D & Half Year Report

31 January 2020, Top 20 Shareholders

News & Announcements 2020By Richard Mollard January 31, 2020

200203_Top_Holders_Report

28 January, Appendix 4C and Quarterly Update

Financial Reports 2020, News & Announcements 2020By Richard Mollard January 28, 2020

200128_Appendix 4C and Quarterly Update

$700K R&D Tax Incentive Refund.

News & Announcements 2020By Richard Mollard January 14, 2020

200114_$700K R&D Tax Incentive Refund

Epichem Awarded DNDi Contract Extension

News & Announcements 2020By Richard Mollard January 8, 2020

200108_Epichem Awarded DNDi Contract Extension

UNITY Announces End to Epichem Contract

News & Announcements 2020By Richard Mollard January 7, 2020

200107_UNITY Announces End to Epichem Contract

31 December, Top 20 Shareholders

News & Announcements 2019By Richard Mollard December 31, 2019

191231_Top Holders 31 December 2019

Expanded Site Recruitment for Monepantel Phase II Trial in Pet Dogs with Cancer

News & Announcements 2019By Richard Mollard December 11, 2019

191211_expanded site recruitment

29 November, Top 20 Shareholders

News & Announcements 2019, Top 20 ShareholdersBy Richard Mollard December 2, 2019

191130_Top_Holders_Report

Pitt Street Research Life Science Conference: Investor Presentation

Investor Presentations 2019, News & Announcements 2019By Richard Mollard November 28, 2019

191128_Investor Presentation

Appendix 3B, Exercise of Options

Financial Reports 2019, News & Announcements 2019By Richard Mollard November 19, 2019

191121_Exercise of Options

Appendix 3B – Exercise of Options

Financial Reports 2019, News & Announcements 2019By Richard Mollard November 8, 2019

191108_Appendix 3B – Exercise of Options

Progress in Recruitment for Phase II Trial in Dogs

News & Announcements 2019By Richard Mollard November 4, 2019

191104_Progress in Recruitment for Phase II Trial in Dogs

Appendix 4C and Quarterly Update

Financial Reports 2019, News & Announcements 2019By Richard Mollard November 1, 2019

191101_Appendix 4C and Quarterly Update

31 October, Top 20 Shareholders

News & Announcements 2019By Richard Mollard November 1, 2019

31 October_Top 20 Shareholders

Epichem New CEO and Board Additions

News & Announcements 2019By Richard Mollard October 14, 2019

191014_Epichem New CEO and Board Additions

Appendix 3B & s708 Notice

Financial Reports 2019, News & Announcements 2019By Richard Mollard October 10, 2019

191010_Appendix 3B & s708 Notice

PharmAust Receives R&D Tax Rebate Pre-Approval

News & Announcements 2019By Richard Mollard October 7, 2019

191007_PharmAust Receives R&D Tax Rebate Preapproval

Epichem Wins Export Award

News & Announcements 2019By Richard Mollard October 4, 2019

191004_Epichem Wins Export Award

PharmAust Raises $2.4 Million in Placement

News & Announcements 2019By Richard Mollard October 3, 2019

191003_PharmAust Raises $2.4million

October 1, Trading Halt

News & Announcements 2019By Richard Mollard September 30, 2019

191001_Trading Halt

30 September 2019, Top 20 Shareholders

News & Announcements 2019By Richard Mollard September 30, 2019

191001_Top Holders September 2019

26 September, Exercise of Options

Financial Reports 2019, News & Announcements 2019By Richard Mollard September 26, 2019

190926_Exercise of Options

24 September, Notice of Annual General Meeting/ Proxy Form

News & Announcements 2019By Richard Mollard September 24, 2019

190924_Notice of Annual General Meeting:Proxy Form

19 September: Appendix 4G & Corporate Governance Statement

Financial Reports 2019, News & Announcements 2019By Richard Mollard September 23, 2019

190919_Appendix 4G & Corporate Governance Statement

19 September: Annual_Report

Financial Reports 2019, News & Announcements 2019By Richard Mollard September 19, 2019

190919_Annual_Report

17 September: Appendix 3B – Exercise of Options

Financial Reports 2019, News & Announcements 2019By Richard Mollard September 17, 2019

190917_Appendix 3B Exercise of Options

Agreement with U-Vet for Phase II Trial in Pet Dogs with Cancer Finalised

News & Announcements 2019By Richard Mollard September 10, 2019

190910_UniMelb_U-Vet Agreement

Investor Roadshow Presentation September 2019

Investor Presentations 2019, News & Announcements 2019By Richard Mollard September 9, 2019

190909_Investor Roadshow Presentation September 2019

Phase II Dog Cancer Trial Commences

News & Announcements 2019By Richard Mollard September 9, 2019

190909_Phase II Dog Cancer Trial Commences

30 August 2019 Top 20 Shareholders

News & Announcements 2019, Top 20 ShareholdersBy Richard Mollard September 2, 2019

Top Holders August 2019

Appendix 4E Preliminary Final Report

Financial Reports 2019, News & Announcements 2019By Richard Mollard August 30, 2019

190830_Preliminary Final Report

Appendix 3B and s708 Notice

Financial Reports 2019, News & Announcements 2019By Richard Mollard August 28, 2019

190828_Appendix 3B & s708 notice

Arrival of GMP Tablets for Phase II Dog Trials

News & Announcements 2019By Richard Mollard August 26, 2019

190826_GMP Tablets Arrive_447v3rv314vgd9

Change of Director’s Interest Notice

News & Announcements 2019By Richard Mollard August 16, 2019

190816_Change of Director's Interest Notice 447k299n9rnrts

31 July 2019 Top 20 Shareholders

News & Announcements 2019, Top 20 ShareholdersBy Richard Mollard July 31, 2019

190731_Top_Holders_Report (33)

Appendix 4C and Quarterly Update

Financial Reports 2019, News & Announcements 2019By Richard Mollard July 30, 2019

4471277nx3858c

Appendix 3B & s708 Notice

Financial Reports 2019, News & Announcements 2019By Richard Mollard July 26, 2019

190729_Unlisted Options Issuance

July 25 Investor Presentation

Investor Presentations 2019, News & Announcements 2019By Richard Mollard July 26, 2019

190725_PAA PRESENTATION 25 JULY 2019

Response to ASX Price and Volume Query

News & Announcements 2019By Richard Mollard July 23, 2019

Response to ASX Price and Volume Query

23 July 2019, Change in Substantial Holding

Financial Reports 2019, News & Announcements 2019By Richard Mollard July 23, 2019

Change in Substantial Holding

Ethics Approval to Use Monepantel Tablet in Dogs with Cancer

News & Announcements 2019By Richard Mollard July 14, 2019

190715_Dog Phase II

Top 20 Shareholders, 5 July 2019

News & Announcements 2019, Top 20 ShareholdersBy Richard Mollard July 5, 2019

190705_Top20Shareholders

PharmAust Featured in BioWorld

News & Announcements 2019By Richard Mollard July 3, 2019

190703_BWT06112019

Epichem’s Completes New Laboratory Financing on Time

News & Announcements 2019By Richard Mollard July 2, 2019

190702_Epichem Loan_Repayment

GMP Manufacture for Phase 2 Canine Trials

News & Announcements 2019By Richard Mollard June 4, 2019

190604_GMP Manufacture

Top 20 Shareholders, 31 May 2019

News & Announcements 2019, Top 20 ShareholdersBy Richard Mollard June 3, 2019

Top_Holders_Report (22)

25 kg of GMP Monepantel from Elanco

News & Announcements 2019By Richard Mollard May 8, 2019

190508_GMP_25kg

30 April, Top 20 Shareholders

News & Announcements 2019, Top 20 ShareholdersBy PharmAust May 6, 2019

Top_Holders_Report (2)

PharmAust Limited Monepantel Tablets Demonstrate High Safety During Phase I Trial

News & Announcements 2019By PharmAust May 3, 2019

Appendix 4C and Quarterly Update

Financial Reports 2019, News & Announcements 2019By Richard Mollard May 1, 2019

444r10lc14lvz2

30 April, Top 20 Shareholders

News & Announcements 2019By Richard Mollard April 30, 2019

Top_Holders_Report (2)

2017 to 2018 R&D Tax Rebate: $672k

News & Announcements 2019By Richard Mollard April 30, 2019

2017:2018 $672k R&D Tax Rebate

Appendix 3B

Financial Reports 2019, News & Announcements 2019By Richard Mollard April 24, 2019

Appendix 3B

11 April: Shortfall Placement Oversubscribed

News & Announcements 2019By Richard Mollard April 11, 2019

190411_Shortfall Placement Oversubscribed

Change of Directors’ Interest: Appendix 3Y

News & Announcements 2019By Richard Mollard March 28, 2019

190329_Directors Interest

Phase I Monepantel Tablets Demonstrate High Safety

News & Announcements 2019By Richard Mollard March 28, 2019

190326_Scaled tablet single dose safety performance (clean)

Top 20 Shareholders, March 2019

News & Announcements 2019, Top 20 ShareholdersBy PharmAust March 27, 2019

PAA Top 20 as at 260319

PharmAust Raises $1.3m in Rights Issue

News & Announcements 2019By Richard Mollard March 22, 2019

190322_Rights Issue Raises 1.3m

Monepantel Tablets Positive Performance in Phase I

News & Announcements 2019By Richard Mollard March 14, 2019

190314_PhaseI part A

Intellectual Property Update

News & Announcements 2019By Richard Mollard March 5, 2019

190305_Intellectual Property Update

Appendix 4D and Financial Report

Financial Reports 2019, News & Announcements 2019By Richard Mollard March 1, 2019

190301_Appendix-4D-and-Financial-Report

Top 20 Shareholders, March 1

News & Announcements 2019, Top 20 ShareholdersBy Richard Mollard March 1, 2019

190301_Top_20 Shareholders March 1

Offer Document – Rights Issue

News & Announcements 2019By Richard Mollard February 25, 2019

190227_Offer_Document

Phase I in Dogs Commences using New Monepantel Tablets

News & Announcements 2019By Richard Mollard February 19, 2019

190220_Phase I starts

Letter to Shareholder

News & Announcements 2019By Richard Mollard February 19, 2019

190219_Letter to Shareholder

Letter to Optionholder

News & Announcements 2019By Richard Mollard February 18, 2019

190218_Letter to Optionholder

Section 708A

Financial Reports 2019, News & Announcements 2019By Richard Mollard February 18, 2019

190218_Section 708A

Non-renounceable Rights Offer

News & Announcements 2019By Richard Mollard February 18, 2019

190218_Non-renounceable rights offer

DNDi Contract Extension

News & Announcements 2019By Richard Mollard February 18, 2019

190218_DNDi_Extension

Appendix 3B

Financial Reports 2019, News & Announcements 2019By Richard Mollard February 18, 2019

190218_Appendix 3B

Appendix 3B Amendment

Financial Reports 2019, News & Announcements 2019By Richard Mollard February 14, 2019

190214_Appendix 3B Amendment

Monepantel Tablet Taste Masking Test Successfully Completed

News & Announcements 2019By Richard Mollard February 10, 2019

190211_taste_test

Section 708A

Financial Reports 2019, News & Announcements 2019By Richard Mollard February 7, 2019

190207_Section 708A

Appendix 3B

Financial Reports 2019, News & Announcements 2019By Richard Mollard February 7, 2019

190207_Appendix 3B

Top 20 Shareholders January 2019

News & Announcements 2019, Top 20 ShareholdersBy PharmAust February 6, 2019

Top_Holder_-_Detail_-_Single_Date january

Tablet Scaled Manufacture for Phase I Trials

News & Announcements 2019By Richard Mollard February 6, 2019

190207_ScaledTablets

Phase I Trial Design

News & Announcements 2019By Richard Mollard February 6, 2019

190207_PhaseIDesign

December 2018 Appendix 4C Quarterly Report and Company Update

Financial Reports 2019, News & Announcements 2019By Richard Mollard January 31, 2019

190131_4C

PharmAust and Elanco Data Sharing Agreement for Dog Trials

News & Announcements 2019By Richard Mollard January 28, 2019

190129_Elanco_tox_package

Monepantel uptake responds to diet and tablet design

News & Announcements 2019By Richard Mollard January 21, 2019

190121_Optimisation of Monepantel Uptake

Monepantel Metabolite Shows Anticancer Activity

News & Announcements 2019By Richard Mollard January 15, 2019

190115_metabolite

PharmAust enters option to license agreement with Elanco for dog cancer treatment

April 18, 2018

Trading Halt

April 16, 2018

Wayne Best appointed Epichem Chairman and Dr Keenan as CEO

April 10, 2018

SECONDARY TRADING NOTICE PURSUANT TO SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001

March 20, 2018

Appendix 3B: New issue announcement, application for quotation of additional securities and agreement

March 16, 2018

Appendix 3Y: Change of Director’s Interest Notice

March 16, 2018

PharmAust new collaboration with leading cancer research institute on its MPL drug candidate

March 14, 2018

Appendix 4D – Half Yearly Report for Dec, 2017

March 1, 2018

PharmAust receives $354k R&D Tax Incentive Refund

February 28, 2018

Top 20 Shareholders Feb 2018

February 26, 2018

Results of General Meeting

February 26, 2018

Appendix 4C and Shareholders Update (Q2, 2018 FY)

January 31, 2018

Monepantel reformulation successfully increases dose and improves taste

January 30, 2018

NOTICE OF GENERAL MEETING AND EXPLANATORY STATEMENT

January 29, 2018

Epichem Awarded One Year Contract Extension from DNDi

January 18, 2018

International Vet Cancer Specialist Joins PharmAust Veterinary Advisory Board

December 17, 2017

Top 20 Shareholders December 2017

December 15, 2017

Phase II Dog Lymphoma Trial Confirms Monepantel Clinical Benefit

December 13, 2017

PharmAust Raises $1.873m via an Oversubscribed Placement

December 6, 2017

Results of AGM 2017

December 1, 2017

Trading Halt Request

December 1, 2017

AGM Presentation 2017

December 1, 2017

PharmAust Identifies New Proprietary Monepantel-related Compounds With Greater Anti-cancer Activity

November 23, 2017

PharmAust secures patent in US for new portfolio of anticancer drugs

November 16, 2017

Dogs needed to help evaluate a promising new anti-cancer drug

November 13, 2017

Epichem Update

November 1, 2017

AGM notice

November 1, 2017

Monepantel reformulation project continues to progress

October 17, 2017

PharmAust secures broad patent in US for non-cancer applications of Monepantel

October 10, 2017

Two key appointments to bolster PharmAust veterinary drug programs

October 3, 2017

Appendix 4C – Quarterly Report and Company Update for the period ended 30 September 2017

September 30, 2017

Reformulation project achieves first milestones and on- track

September 20, 2017

PharmAust secures core Europe patent

September 12, 2017

PharmAust and Nihon Nohyaku Japan Enter Assignment Agreement of Joint Patents

September 4, 2017

Appendix 4G

August 31, 2017

Investor Presentation (August)

August 31, 2017

Shareholders Update

August 22, 2017

Epichem Reports Record $3m Revenues and Expands Laboratory to Accelerate Growth

July 17, 2017

Appendix 4E & Annual Report

July 10, 2017

Appendix 4C – Quarterly Report & Company Update for the period ended 30 June 2017

June 30, 2017

PharmAust engages Canadian-based specialists to reformulate monepantel

June 27, 2017

PharmAust secures broad European patent for non-cancer applications

June 8, 2017

PharmAust secures core patent in Japan

June 6, 2017

PharmAust Shareholders Update and Roadmap

May 30, 2017

Phase II dog lymphoma trial preliminary results demonstrate Monepantel clinical benefit

May 19, 2017

PharmAust secures broad patent coverage for non-cancer applications

May 17, 2017

Investor Presentation (May)

May 10, 2017

PharmAust secures core China patent

May 5, 2017

Appendix 4C – Quarterly Report & Company Update for the period ended 31 March 2017

April 13, 2017

Dr Richard Mollard appointed as Chief Scientific Officer of PharmAust

March 8, 2017

PharmAust raises a further $534K

March 3, 2017

Dr Richard Hopkins Appointed as CEO of PharmAust

March 1, 2017

Appendix 4C – Quarterly Report & Company Update for the period ended 31 December 2016

January 31, 2017

PharmAust receives $406K R&D rebate from ATO

January 30, 2017

Appendix 4D Half-Year Report for the period ended 31 December 2016

December 31, 2016

Appendix 4D Half-Year Report for the period ended 31 December 2016

December 31, 2016

Appendix 4D & Half Yearly Report and Accounts

December 31, 2016

PharmAust raises a further 1.56m

December 30, 2016

Completion of rights issue and notice shortfall

December 8, 2016

Rights issue – Extension of closing date

December 5, 2016

No extension of closing date in rights issue

December 5, 2016

Phase II Strategy Update

November 21, 2016

Results of annual general meetings

November 11, 2016

Appendix 3B

November 11, 2016

Notice of annual general meeting and explanatory statement

November 11, 2016

PharmAust Limited (ASX – PAA) Secondary trading notice

November 10, 2016

PharmAust AGM presentation

November 10, 2016

Non renounceable rights offer

November 7, 2016

Prospectus

November 1, 2016

Appendix 4C – Quarterly Report & Company Update for the period ended 30 September 2016

October 31, 2016

Second canine receives treatment in trial

October 14, 2016

Phase II canine trial begins at the university of Cambridge

September 19, 2016

Epichem achieves ISO 90001-2015 certification

September 16, 2016

MPL capsules shipped to centres in NSW & Qld for Phase II

September 13, 2016

PharmAust Investor Presentation – June 2016

August 10, 2016

Further Canine Trials to be Initiated in Australia

August 10, 2016

IP exchange with UNSW consolidates MPL patent position

August 3, 2016

Reformulated MPL capsules completed, Phase II to commence

July 11, 2016

Appendix 4E Annual Report & Full Year Statutory Accounts 2016

July 1, 2016

Appendix 4G & Corporate Governance Statement

June 30, 2016

University of Cambridge to begin Phase II Trial

June 27, 2016

Epichem Successful in AusTrade Grant

June 16, 2016

Epichem Successful in AusTrade Grant

June 16, 2016

Mandate signed to raise capital in USA & list on NASDAQ

May 3, 2016

Appendix 4C Quarterly Report & Brief Company Update

April 29, 2016

RedChip issues research on PharmAust

March 11, 2016

Strategy for Phase II Clinical Trial of Monepantel

March 8, 2016

PharmAust Featured on The RedChip Money Report on Bloomberg

February 12, 2016

PharmAust to Present at RedChip Global Online Microcap Conf

February 8, 2016

Notice of Allowance received from USA Patent OffIce

February 5, 2016

PharmAust Receives $546K R&D Rebate from ATO

February 1, 2016

Appendix 4C – Quarterly Report & Company Update

January 29, 2016

Juniper Pharma Services to reformulate MPL for Phase II

January 11, 2016

PharmAust Featured on RedChip Money Report on Bloomberg

January 4, 2016

Epichem Successful in AusTrade Grant

June 16, 2015

PharmAust Broker Roadshow Presentation – April 2015

April 17, 2017

USA Roadshow Presentation – January 2016

January 15, 2016

Epichem Awarded Two Year Contract Extension from DNDi

December 21, 2015

Appendix 3B & 708 Notice

December 4, 2015

Change of Director’s Interest Notice

December 3, 2015

GenScript Further Pre-Clinical Validation for Phase II Trial

November 26, 2015

RedChip appointed to begin Global Investor Relations Program

November 24, 2015

Change of Director’s Interest Notice

November 13, 2015

Appendix 3B

November 5, 2015

Appendix 4C Quarterly Report & Company Update

October 30, 2015

Consolidation of Capital

October 27, 2015

Results of Annual General Meetings 2015

October 27, 2015

PharmAust AGM Presentation 2015

October 27, 2015

Change of Director’s Interest Notice

October 22, 2015

Notice of Annual General Meeting

October 22, 2015

Clinical Trial Report Following Phase I Trial

October 21, 2015

Change of Registered Office & Principal Place of Business

October 19, 2015

Epichem’s New Laboratory Completed

September 29, 2015

Consolidation_Split – PAA

September 22, 2015

Appendix 3B & 708 Notice

September 4, 2015

PharmAust Annual Report 2015

August 28, 2015

Final Director’s Interest Notice

August 27, 2015

Professor Morris plans to retire from PharmAust board

August 25, 2015

Change of Director’s Interest Notice

August 11, 2015

Clarification on Expiry of Listed Options

August 3, 2015

Letter to Optionholders

July 31, 2015

Phase I Trial at RAH Meets Safety & Cancer Marker End Points

July 23, 2015

Trading Halt

July 22, 2015

First Two Canines Complete Combination Therapy With PPL-1

July 17, 2015

Appendix 4G & Corporate Governance Statement

June 30, 2015

Appendix 4E & Full Year Statutory Accounts

June 30, 2015

Appendix 4C – Quarterly Report & Company Update

June 30, 2015

PharmAust Receives ATO Research & Development Rebate

June 24, 2015

PharmAust Initiates Combination Therapy Evaluations in Dogs

June 17, 2015

Change of registry address

June 12, 2015

Results of Meeting

May 26, 2015

Notice of General Meeting_Proxy Form

May 26, 2015

EGM Shareholder Presentation

May 26, 2015

Second Dog Shows Suppression of Cancer Marker at Days 3 & 7

May 19, 2015

Reduction of further Cancer Marker confirmed in Human Trial

May 14, 2015

First Dog Shows Suppression of Cancer Marker

May 1, 2015

Approval of Dose Escalation of PPL-1 in Human Trial

April 15, 2015

Modification of Clinical Trial in Dogs

April 13, 2015

PharmAust Broker Roadshow Presentation – April 2015

April 10, 2015

Lyell McEwin Hospital approved to join PharmAust trial

April 8, 2015

Appendix 4C Quarterly Report & Company Update

March 31, 2015

Joint Patent with Japanese Corporation now published

March 30, 2015

Final Patient in Cohort Demonstrates Tumour Marker Reduction

March 24, 2015

Appendix 3B and s708 Notice

March 20, 2015

Completion of Lowest Dose Cohort in Human Cancer Trial

March 17, 2015

PharmAust completes $3.14m Share Placement oversubscribed

March 16, 2015

PharmAust Shareholder Presentation – March 2015

March 15, 2015

Trading Halt

March 12, 2015

American Assoc for Cancer accepts Late-Breaking Abstract

March 6, 2015

Human Trial Prelim Results Shows Reduction in Tumour Markers

February 9, 2015

Clarification to Quarterly Report & Company Update

February 3, 2015

Appendix 4C – Quarterly Report & Company Update

January 30, 2015

Shareholder Update – Human & Canine Trials

January 25, 2015

Appendix 4D and Half Yearly Report & Accounts

December 31, 2014

Change of Director’s Interest Notice

November 26, 2014

Change of Director’s Interest Notice

November 24, 2014

Change of Director’s Interest Notice

November 24, 2014